Loading stock data…
$30.42+0.89 (+3.01%)
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
Caris Life Sciences, Inc. in the Healthcare sector is trading at $30.74 with a market capitalization of $8.0B. Wall Street consensus targets $30.85 (13 analysts), implying a +0.3% move over the next 12 months. The stock is currently near its 52-week high of $33.65, remaining 44.6% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $263.71M↑ | $216.17M↓ | $292.89M↑ | $216.83M↑ | $181.40M |
| Gross Profit | $179.60M↑ | $141.35M↓ | $220.91M↑ | $147.51M↑ | $113.69M |
| Operating Income | $26.93M↑ | $5.28M↓ | $88.41M↑ | $32.64M↑ | -$17.99M |
| Net Income | -$637,000↓ | -$510,000↓ | $81.96M↑ | $24.32M↑ | -$71.79M |
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and a...